Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RESEARCH TOOLSreports
Holding RNAC?
Track your performance easily
RNAC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.67 - $42.60
Previous Close$16.63
Volume122.02K
Average Volume (3M)146.52K
Market Cap
$355.67M
Enterprise Value$283.31M
Total Cash (Recent Filing)$87.23M
Total Debt (Recent Filing)$14.87M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 08, 2024EPS Estimate
-$0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-53.26
Shares Outstanding21,382,485
10 Day Avg. Volume71,316
30 Day Avg. Volume146,517
Standard Deviation0.25
R-Squared0.02
Alpha-0.00048
Financial Highlights & Ratios
Price to Book (P/B)-3.51
Price to Sales (P/S)6.33
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.24
Enterprise Value/Gross Profit10.90
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$42.00Price Target Upside168.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Cartesian Therapeutics News
PremiumCompany Announcements
Cartesian Therapeutics Engages Investors at Conferences
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyEncouraging topline data from the company's Phase 2b trial of DC-08 in MG showed competitive efficacy and a clean safety profile with no CRS or ICANS.
Indication ExpansionIndication expansion opportunities for DC-08 in systemic lupus erythematosus, where RNAC recently initiated an open-label Phase 2 study.
Regulatory AdvantageRare Pediatric Disease designation received for Descartes-08 in juvenile dermatomyositis, providing Cartesian with the opportunity to receive a Priority Review Voucher (PRV) upon approval.
Bears Say
Clinical TrialsTherapeutics have faced challenges in tough indications like DM, with Kezar's KZR-616 failing to meet its primary endpoint.
Competitive LandscapeRoche/Chugai's decision to discontinue further development of Enspryng in MG indicates potential downside risk even if results are statistically positive.
Dilution RiskPossible long-term dilution risk could negatively impact stock value.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $11.66 and its highest was $42.60 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Currently, no data Available
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is 43 days ago.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on May 08, 2024. The company reported -$10.5 earnings per share for the quarter, missing the consensus estimate of -$0.885 by -$9.615.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -$0.86.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 21,387,548 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$10.5 in its last earnings report, missing expectations of -$0.885. Following the earnings report the stock price went down -9.43%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Among the largest hedge funds holding Cartesian Therapeutics’s share is Delphi Financial Group, Inc.. It holds Cartesian Therapeutics’s shares valued at 595K.
---
Cartesian Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.00 (168.71% Upside)
$42.00 (168.71% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 442.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $197.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
149.26%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
---
RNAC Earnings Call
Q2 2023
0:00 / 0:00
---
RNAC Stock 12 Month Forecast
Average Price Target
$42.00
▲(168.71% Upside)
Technical Analysis
Best Analysts Covering RNAC
1 Year
---